{
    "nct_id": "NCT06534983",
    "official_title": "A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma",
    "inclusion_criteria": "* Histologically confirmed muscle-invasive UC (also termed TCC) of the bladder or upper urinary tract\n* TNM classification (UICC/AJCC 7th edition) at pathological examination of surgical resection specimen of (y)pT3-4 or (y)pN+ and M0\n* Surgical resection of MIUC of the bladder or upper tract\n* Participants who have not received prior neoadjuvant cisplatin chemotherapy (NAC) must be ineligible to receive adjuvant cisplatin therapy due to patient refusal, cisplatin ineligibility or investigator decision\n* Tumor tissue must be provided for biomarker analysis\n* Absence of residual disease and absence of metastasis, as confirmed by a negative baseline Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan of the pelvis, abdomen, and chest no more than 28 days prior to randomization.\n* Full recovery from cystectomy or nephroureterectomy within 120 days following surgery\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Negative HIV test at screening\n* No evidence of active hepatitis B, defined as having a negative hepatitis B surface antigen (HbsAg) test at screening\n* Negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test followed by a negative HCV RNA test at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Partial cystectomy in the setting of bladder cancer primary tumor or partial nephroureterectomy in the setting of renal pelvis primary tumor\n* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment\n* Any prior neoadjuvant immunotherapy\n* Adjuvant chemotherapy or radiation therapy for UC following surgical resection\n* Malignancies other than UC within 5 years prior to randomization\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment",
    "miscellaneous_criteria": ""
}